Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR-ATAC: Fresolimumab + SABR in Early Stage NSCLC
NCT02581787Phase 2Completed
- Sponsor
- Maximilian Diehn
- Start
- Aug 2016
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fresolimumab in non-small cell lung cancer (NSCLC), sponsored by Maximilian Diehn. Started Aug 2016; status: completed.
02
Drugs
fresolimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02581787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581787.